Patient Profiles

Consider XYNTHA for your patients who live actively

For your active patients who are adventurous —
ACTIVE IS crew practice during the week, jogging whenever he gets a chance, and a fishing trip this weekend​​​​​​​

Age: 

Header

This text is for block level content. P tags can go in here too

  • 20

Lifestyle:

  • Dorm-living student athlete
  • Active class, sport, and work schedules

Treatment Needs:

  • A treatment indicated to treat and control bleeds
  • The flexibility to infuse with a travel-ready kit
See the efficacy of XYNTHA demonstrated in clinical trials


​​​​​​​For your active patients who live on the go —
​​​​​​​
ACTIVE IS the office soccer league 2 days a month, maybe a hike on Saturday, and helping a friend move next weekend

Age: 

  • 28

Lifestyle:

  • Travels frequently for work
  • Busy and unpredictable social and work schedules
  • Often makes spur-of-the-moment plans with friends

Treatment Needs:

  • A treatment indicated to treat and control bleeds
  • Portability for a life on the go
See what XYNTHA SOLOFUSE offers


​​​​​​​For your active patients who do it themselves —
​​​​​​​
ACTIVE IS coaching his son's soccer game, doing some repairs around the house, and a whole lot of yard work this weekend

Age:

  • 42

Lifestyle:

  • Small business owner with big responsibilities
  • Married with 2 young children

Treatment Needs:

  • A treatment that allows him to infuse on the go
  • Bleed protection when he needs it
See the proven bleed control of XYNTHA SOLOFUSE


​​​​​​​For your patients who are always running around —
​​​​​​​
ACTIVE IS an afternoon on his scooter, T-ball practice during the week, and fun at a birthday party this weekend

Age: 

  • 5

Lifestyle:

  • A ball of energy on the school playground
  • Extremely social at school, at home, and in his swimming class
  • Always on an adventure and exploring his independence

Treatment Needs:

  • His parents want a treatment that can control bleeds and help him live actively
See how XYNTHA SOLOFUSE can help

All-In-One Reconstitution

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

See the device

** This is an optional area where footnotes can live.

  • Do not use in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster proteins.
  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with XYNTHA. Inform patients of the early signs or symptoms of hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, and hypotension) and anaphylaxis. Discontinue XYNTHA if hypersensitivity symptoms occur and administer appropriate emergency treatment. XYNTHA contains trace amounts of hamster proteins. Patients may develop hypersensitivity to these proteins.
  • Inhibitors have been reported following administration of XYNTHA. Monitor patients for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • Clinical response to XYNTHA may vary. If bleeding is not controlled with the recommended dose of factor, determine the plasma level and administer a dose of XYNTHA sufficient to achieve clinical response. If the factor level does not increase or there is no response, suspect an inhibitor and perform appropriate testing.
  • Across all studies, the most common adverse reactions (≥10%) with XYNTHA in previously treated adult and pediatric patients were headache (24% of subjects), arthralgia (23%), fever (23%), and cough (12%). Other adverse reactions reported in ≥5% of subjects were diarrhea, vomiting, and weakness.
  • XYNTHA is an injectable medicine administered by intravenous (IV) infusion. Patients should be advised that local irritation may occur when infusing XYNTHA after reconstitution in XYNTHA® SOLOFUSE®.

XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, for perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes. 

XYNTHA is not indicated in patients with von Willebrand’s disease. 

Please see full Prescribing Information for XYNTHA and XYNTHA SOLOFUSE.

Indication

XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, for perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes. 

XYNTHA is not indicated in patients with von Willebrand’s disease. 

Please see full Prescribing Information for XYNTHA and XYNTHA SOLOFUSE.